Home > Browse Issues > Vol.38 No.6
The Onward March of TRAIL Resistance
Sia Youyang, Lin Juiming, Xu Weirong*
Teaching Lab Center for Basic Medicine, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China
Abstract: The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising candidate for cancer therapy. Its property of being able to target cancer cells specifically while leaving normal cells unharmed has drawn the attention of researchers， and has entered phase II of clinical trials. Even though reports have indicated that resistance towards TRAIL has developed in a number of cancer cells， the prospect of using TRAIL to combat cancer remain positive. Understanding the mechanisms of TRAIL resistance will greatly aid in the search of targets to overcome TRAIL resistance， and through regulating related signaling molecules with the help of concomitant drugs， better anticancer results may be achieved. This review will cover TRAIL， its apoptotic pathway， and summarize the mechanisms of TRAIL resistance along with methods to reduce this resistance found in recent years.
CN
EN